CIC and Parkwalk have returned to back patient-focused genomic analysis developer Congenica, bringing its funding total to $85m.
Congenica, a UK-based patient genomic testing service provider based on research from Wellcome Sanger Institute and the UK’s National Health Service (NHS), closed a £39m ($50m) series C round on Friday featuring Cambridge Innovation Capital (CIC), the VC investor focused on the Cambridge, UK ecosystem.
The round was co-led by internet group Tencent and insurance provider Legal & General with participation by Parkwalk Advisors, part of commercialisation firm IP Group, as well as Xeraya Capital, Puhua Capital, IDO Investments and Downing Ventures.
Founded in 2014, Congenica produces genomic analysis software used by research labs to scrutinise genetic samples extracted from next-generation DNA sequencers.
The software is underpinned by machine learning which Congenica claims is able to process hundreds of human genomes in a single day.
The series C cash is expected to help Congenica strike industry partnerships as it looks to enter more international markets and clinical…
